52 results about "Cellular localization" patented technology

The present invention is directed to a method for detection, characterization and isolation of nucleic acids encoding proteins of a desired property, such as a particular cellular localization. The invention further provides for rapid expression of such proteins or glycoproteins in mammalian cells and for facilitated purification of the novel secreted proteins or glycoproteins. Further, the invention provides for radioactive labelling of the novel proteins or glycoproteins, for rapid identification of sites of binding including animals and for rapid production of infective viral vectors for use in gene transfer.

The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and / or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and / or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.

The invention relates to kinase inhibitor ligands and polyligands. In particular, the invention relates to ligands and polyligands that modulate ERK activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to a cellular localization signal, epitope tag and / or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.

The invention provides a cellular localization unit, array and device and a formation method of the cellular localization unit, array and device. The cellular localization unit comprises a substrate and a cellular localization hole. At least one pair of microelectrodes is arranged on the substrate; the microelectrodes are separated and each pair of the electrodes is symmetrically dispersed relatively to the same point to generate a normal dielectrophoretic force area at an area where the ends of the microelectrodes gather; and voltage signals connected to adjacent microelectrodes have opposite phases. The cellular localization hole is located above the microelectrodes; the accommodation room of the cellular localization hole exposes the normal dielectrophoretic force area; and the accommodation room is for a single cell. AC signals with certain amplitudes, frequencies and phases are applied to the microelectrodes, so that cells move towards the surfaces of the microelectrodes, and the cellular localization hole matches the microelectrodes to allow a single cell to be accurately localized at a certain position.

Reagents, methods, and kits for the classification of cancer that comprise or employ antibodies that bind specific regions of CD43. One method includes contacting tissue with an antibody capable of specifically binding the cytoplasmic tail of CD43, contacting the tissue with an antibody capable of specifically binding the extracellular domain of CD43, and resolving cellular localization of any binding to the tissue with the antibody capable of specifically binding the cytoplasmic tail of CD43 and the antibody capable of specifically binding the extracellular domain of CD43. The binding patterns of the antibodies can be used to characterize cancer as more aggressive or less aggressive and can distinguish small cell lung cancer from non-small cell lung cancer. The cancer may therefore be treated in accordance of the characterization.

With the goal of creating a combination vaccine against Shigella and other diarrheal pathogens we have constructed a prototype vaccine strain of Shigella flexneri 2a (SC608) that can serve as a vector for the expression and delivery of heterologous antigens to the mucosal immune system. SC608 is an asd derivative of SC602, a well-characterized vaccine strain, which has recently undergone several phase 1 and 2 trials for safety and immunogenicity. Using non-antibiotic asd-based plasmids, we have created novel constructs for the expression of antigens from enterotoxigenic E. coli (ETEC), including CFA / I (CfaB and CfaE) and the B-subunit from heat-labile enterotoxin (LTB) in Shigella vaccine strain SC608. Heterologous protein expression levels and cellular localization are critical to immune recognition and have been verified by immunoblot analysis. Following intranasal immunization (SC608(CFAI) and SC608(CFAI / LTB) of guinea pigs, serum IgG and IgA immune responses to both the Shigella LPS and ETEC antigens can be detected by ELISA. In addition, ELISPOT analysis for ASCs from cervical lymph nodes and spleen showed similar responses. All vaccine strains conferred high levels of protection against challenge with wild-type S. flexneri 2a using the Sereny test. Furthermore, serum from guinea pigs immunized with SC608 expressing CfaB and LTB contained antibodies capable of neutralizing the cytological affects of heat-labile toxin (HLT) on Chinese Hamster Ovary (CHO) cells. These initial experiments demonstrate the validity of a multivalent invasive Shigella strain that can serve as a vector for the delivery of pathogen-derived antigens.

A method of determining whether a subject is at risk of developing osteoarthritis (OA), said method comprising: determining the cellular localization of a Prohibitin-1 (PHB1) polypeptide and / or Small Ubiquitin-like Modifier (SUMO) polypeptide and / or UBC9, in a cell sample from said subject; and determining whether said subject is at risk of developing OA based on the cellular localization of a PHB1 polypeptide and / or SUMO and / or UBC9 polypeptide, is described.

Methods and kits for the prognosis of breast cancer comprising measurement of nuclear Ep-ICD poly-peptides are provided. Measurement may be quantitative and / or qualitative. The invention also provides a system for generating an Ep-ICD Subcellular Localization Index (ESLI) value, which may be used to prognose breast cancer in a subject.